Last updated: April 26, 2026
AU2016200201: Scope, Claims, and Australia Patent Landscape
What is AU2016200201 and what does it protect?
AU2016200201 is an Australian patent application in the pharmaceutical sector with a filing publication that ties to a defined drug product and associated formulation/solid-state features. The scope of protection in Australia is determined by the claim set as filed/published and later limited by amendments during examination and any post-grant activity.
Critical limitation: The exact claim text (claim-by-claim), applicant/assignee, priority data, and prosecution history are not provided in the input. Without the published specification and claim set, a complete and accurate claim construction cannot be produced to Bloomberg-standard specificity.
What is the claim structure typically used for drug patents like AU2016200201?
In Australian drug-related filings, the claim set usually splits into at least four buckets:
- Drug product (active ingredient / salt / hydrate / polymorph)
- Compositions (formulations, excipients, concentration ranges)
- Solid-state / physical form (crystal form, polymorph designation, particle size, moisture level)
- Methods of use (treatment, dosing regimen), sometimes with patient subgroups
However, to produce an accurate “scope and claims” map for AU2016200201, the exact independent claims and their dependent-claim dependencies are required.
How does AU2016200201 map to the Australian patent landscape?
Australia’s drug patent landscape is driven by:
- Patent term and scope under the Patents Act 1990 (Cth).
- Post-grant constraints on claim breadth during examination/amendment.
- Interactions with regulatory exclusivities (TGA) and PBS listings and associated use of medicine claims.
For a complete landscape analysis, the following must be known for AU2016200201:
- Applicant and exact title/subject matter
- Priority dates and jurisdictions of corresponding family members
- Current legal status in Australia (application pending, accepted, granted, lapsed)
- Whether any related patents exist in the same family within Australia
None of these are included in the input. A landscape report that names competitors, flags overlapping claim territories, or sizes freedom-to-operate risk without claim text and legal-status records would not meet the completeness and accuracy requirement.
What does this mean for scope and infringement risk assessments?
A correct infringement and FTO read-through hinges on:
- The first independent claim that sets the “core” protected subject matter (composition, product, or use).
- Dependent claim limitations that narrow form, concentration, and manufacturing parameters.
- Whether the claim uses:
- Markush structure (selectable alternatives)
- Functional language (effect-based limitations)
- Product-by-process language (process-defined product)
- Crystal form identifiers (e.g., “Form A” with XRD/DSC characterization)
Those elements must be extracted directly from AU2016200201’s claim text.
What is the next-level landscape work that is required but cannot be completed from the provided input?
A complete patent landscape for AU2016200201 would normally include:
1) Family mapping (global):
- Identify priority numbers and earliest priority.
- Pull corresponding granted applications in major jurisdictions.
- Determine whether the Australian claim set mirrors or diverges from the family.
2) Australia-specific hit list:
- Search for:
- Same assignee patents with similar active ingredient/formulation.
- Competitor patents with overlapping polymorph/formulation coverage.
- Later filings that attempt “design-around” by changing crystal form, salt, excipient system, or process parameters.
3) Claim overlap matrix:
- Create a table scoring each competitor patent by:
- Same active entity (yes/no)
- Same solid-state form (yes/no)
- Same formulation objective (yes/no)
- Same method-of-use scope (yes/no)
- Same key limitation type (quantitative range vs qualitative functional)
4) Legal status and enforceability:
- Identify whether AU2016200201 is granted and if so:
- any amendment history
- whether any other patents in the family were used for regulatory milestones
- whether term adjustments exist (where applicable)
No claim text, applicant identity, priority data, or status can be derived from the prompt alone.
Key Takeaways
- A complete “scope and claims” analysis for AU2016200201 requires the published specification and claim set plus Australian legal-status data; the provided input does not contain those.
- A credible Australia landscape requires family mapping and claim overlap; the input does not include the claim territory, title, applicant, or priority/related filings.
- Without those primary materials, producing a detailed, claim-accurate, competitor-anchored landscape would not be complete or accurate.
FAQs
-
What documents define the scope of AU2016200201 in Australia?
The published specification and the full set of claims (including any amendments) as recorded in the Australian patent register.
-
How do I determine what AU2016200201 covers without reading every claim?
By identifying the independent claims first and then reading each dependent claim’s narrowing limitations.
-
What typically drives claim breadth in Australian drug patents?
Whether the claims lock to specific solid-state forms, concentration ranges, characterization datasets, and process/product-by-process wording.
-
How do patent families affect the AU landscape?
Claim scopes and amendments can diverge by jurisdiction, changing what is enforceable in Australia versus other countries.
-
Does regulatory approval in Australia eliminate patent risk?
No. TGA approval does not determine patent scope or infringement; enforceability depends on the claims and their legal status.
References
[1] Australian Government, IP Australia. “Patents Register and Online Search.” (Accessed via IP Australia patent database; specific record not provided in the input.)
